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Jakob Kreye1,2,3,4,5, Sukhvir K. Wright6,7, Adriana van Casteren1, Laura Stöffler1,3, Marie-Luise Machule1,3, S. Momsen Reincke1,2,3,5,
Marc Nikolaus4,7,8, Scott van Hoof1,2,3, Elisa Sanchez-Sendin1,2,3, Marie A. Homeyer1,3, César Cordero Gómez1,3, Hans-Christian Kornau1,9,
Dietmar Schmitz1,9, Angela M. Kaindl4,8,10, Philipp Boehm-Sturm3,9, Susanne Mueller3,9, Max A. Wilson6, Manoj A. Upadhya6,
Divya R. Dhangar6, Stuart Greenhill6, Gavin Woodhall6, Paul Turko11, Imre Vida11, Craig C. Garner1, Jonathan Wickel12,
Christian Geis12, Yuko Fukata13,14, Masaki Fukata13,14, and Harald Prüss1,2,3
Autoantibodies targeting the GABAA receptor (GABAAR) hallmark an autoimmune encephalitis presenting with frequent
seizures and psychomotor abnormalities. Their pathogenic role is still not well-defined, given the common overlap with further
autoantibodies and the lack of patient-derived mAbs. Five GABAAR mAbs from cerebrospinal fluid cells bound to various
epitopes involving the α1 and γ2 receptor subunits, with variable binding strength and partial competition. mAbs selectively
reduced GABAergic currents in neuronal cultures without causing receptor internalization. Cerebroventricular infusion of
GABAAR mAbs and Fab fragments into rodents induced a severe phenotype with seizures and increased mortality,
reminiscent of encephalitis patients’ symptoms. Our results demonstrate direct pathogenicity of autoantibodies on GABAARs
independent of Fc-mediated effector functions and provide an animal model for GABAAR encephalitis. They further provide the
scientific rationale for clinical treatments using antibody depletion and can serve as tools for the development of antibody-
selective immunotherapies.
Introduction
γ-Aminobutyric acid receptors of class A (GABAARs) are key
molecules for physiological brain function, transmitting rapid
phasic inhibitory synaptic signaling and mediating tonic inhi-
bition at extrasynaptic and perisynaptic locations (Farrant and
Nusser, 2005). The pentameric ligand-gated chloride channels
can be composed of different subunits (α1–6, β1–3, γ1–3, δ, ε, π, θ,
and σ1–3), most abundantly in the α1β2γ2 configuration (Olsen
and Sieghart, 2008). Receptor dysfunction can lead to severe
neurological symptoms, such as epileptic encephalopathies
based on GABAAR subunit mutations (Hernandez et al., 2019;
Lachance-Touchette et al., 2010; Maljevic et al., 2006; Wallace
et al., 2001). Recently, cerebrospinal fluid (CSF) and serum
autoantibodies targeting the α1-, β3-, and γ2-subunits of GA-
BAARs were identified in a new form of autoimmune enceph-
alitis presenting with seizures, refractory status epilepticus,
cognitive alterations, psychomotor disorders, and magnetic
resonance imaging abnormalities (Ohkawa et al., 2014; Petit-
Pedrol et al., 2014; Pettingill et al., 2015; Spatola et al., 2017).
Patients’ sera or CSF containing polyclonal GABAAR antibodies
caused down-regulation of surface GABAAR and electrophysi-
ological changes in cultured neurons (Ohkawa et al., 2014;
Petit-Pedrol et al., 2014; Pettingill et al., 2015).
Patients with GABAAR encephalitis frequently harbor further
established pathogenic autoantibodies such as those targeting
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Leucine-rich, glioma inactivated 1 (LGI1), Contactin associated
protein 1 (CASPR2), and N-methyl-D-aspartate receptor (NMDAR;
Ohkawa et al., 2014; Petit-Pedrol et al., 2014; Pettingill et al., 2015);
hence, it is unclear whether the observed effects exclusively relate
to GABAAR antibodies. Interestingly, in a subset of patients, an-
tibodies against intracellular glutamic acid decarboxylase 65
(GAD65) were observed (Petit-Pedrol et al., 2014), and recently,
strongly expanded CD8+ T cell clones have been described
(Bracher et al., 2020), both pointing toward an accompanying
T cell–driven immune response.
In this current study, we aimed to characterize the intra-
thecal human mAb repertoire from antibody-secreting cells
(ASCs) and B cells from CSF in acute GABAAR encephalitis. Using
recombinant production of CSF-derived mAbs (Kornau et al.,
2020; Kreye et al., 2016), we generated a set of GABAAR mAbs
for the characterization of antibody sequence features, epitope
mapping, and pathogenic functional effects in vitro and in vivo,
independent of confounding factors.
Results
Monoclonal CSF antibodies from an encephalitis patient target
GABAAR and non-GABAAR antigens
To investigate the functional role of GABAAR antibodies in en-
cephalitis pathogenesis, we first explored the monoclonal Ig
repertoire in the CSF of a pediatric GABAAR encephalitis patient
presenting with catatonia (Nikolaus et al., 2018). The antibody re-
sponse was captured from single cells of three populations: CD138+
ASCs, CD20+CD27+ memory B cells (MBCs), and CD20+CD27−
nonmemory B cells (NMBCs), separated via fluorescence-activated
cell sorting (Fig. S1 A). Using single-cell cloning (Kreye et al., 2020;
Kreye et al., 2016), we generated 67 recombinant human mAbs,
which were screened for GABAAR reactivity on cell-based assays
(CBAs) and on unfixed murine whole brain sections as an unbiased
test for central nervous system (CNS) auto-reactivity.
We identified five different human GABAAR mAbs. Four re-
acted positive in two CBAs using human embryonic kidney
(HEK) cells expressing either α1β3 (comparable to clinical rou-
tine assays) or α1β3γ2 GABAARs (Fig. S1 B). In contrast, mAb
#113-175 bound to GABAARs on the α1β3γ2 CBA only (Fig. S1 B).
All five mAbs revealed strong tissue reactivity on murine brain
sections (Fig. 1, A–C; and Fig. S3, A–D), most prominently against
hippocampal neuropil (Fig. 1, A and B), the granule cell and
molecular layer in the cerebellum, putamen, and olfactory bulb.
Reactivity to the extracellular domain of GABAARwas confirmed
on cultured live rat neurons (Fig. 1 C) and showed a clustered
distribution of GABAARs along Microtubule-associated protein
2 (MAP2)–positive dendrites (Fig. 1 D), overlapping with a
commercial rabbit GABAAR-α1 antibody and colocalizing with
presynaptic vesicular GABA transporter (VGAT; Fig. 1 E). In
addition to a typical neuronal GABAAR-binding pattern, #113-201
revealed intense reactivity against choroid plexus and around
blood vessels (Fig. S2, C and E), in locations where no β1-, β2-, or
β3-subunits could be detected (Fig. S2, F–H). β-subunits are
essential for functional GABAAR, thus indicating an additional
target for #113-201 independent of GABAAR. #113-201 (and all
other GABAAR mAbs) did not bind to established polyreactivity-
defining antigens (Fig. S1, J–O), suggesting that this additional
reactivity is specific to a distinct target rather than a feature of
unspecific binding to a broad variety of antigens.
17 of the expressed GABAAR-negative mAbs (27.9%) showed
intense tissue binding on unfixed murine brain sections in
distinct patterns, mostly on neuronal surfaces of the hippo-
campus, the cerebellum, and in basal ganglia, but others also
against blood vessels, choroid plexus, ependyma, and white
matter tracts (Fig. 1, F–J; and Fig. S2, I–P). A subset also reacted
with fixed cultured neurons (Fig. 1, H–J, inserts). Screening for
already established neuronal antigens with commercial assays
identified Homer-3 as the target of #113-212 (Fig. 1 J), while the
other non-GABAAR antigens remained unknown.
Polyclonal response to GABAARs derived mainly from IgG1
antibody–secreting cells
We next investigated sequence features of the GABAAR en-
cephalitis Ig repertoire. mAbs derived from different cell pop-
ulations revealed characteristic Ig isotype distributions (Fig. S1 C
and Table S1). All GABAAR mAbs were of the IgG1 subtype (Fig.
S1 D) and derived predominantly fromASCs, also from oneMBC,
but not fromNMBCs (Fig. S1 E). In contrast, CNS tissue-reactive,
but GABAAR-negative mAbs were similarly distributed within
different cell populations (Table S1). Among all mAb sequences,
no clonal relationships were identified, indicating a polyclonal
response to GABAARs. Compatible with affinity maturation well
known from B cells in other compartments, CSF-derived mAbs
from MBCs carried more somatic hypermutations (SHMs) than
mAbs from NMBCs on heavy chains, light chains, and per mAb
in total (22.6 ± 12.8 vs. 10.1 ± 8.6; P = 0.0001, ANOVA, post hoc
Tukey’s multiple comparisons test; Fig. S1 F and Table S1). SHM
counts of ASC mAbs (14.2 ± 1.9) were between those of MBC and
NMBC mAbs (Fig. S1 F). GABAAR mAbs contained a similar
number of SHMs as GABAAR-negative mAbs (Fig. S1 G). Within
GABAAR mAbs, SHMs were higher in frequency and replace-
ment to silence ratios in complementarity-determining regions
(CDRs) than in frame regions (FRs; Fig. S1, H and I), character-
istic of antigen-driven maturation.
Patient-derived mAbs bound α1- and γ2-subunits of GABAAR
with different strengths and partial competition
To select the most relevant antibodies for functional studies, we
aimed to characterize the subunit specificity and the binding
strength of the isolated GABAARs mAbs. To this end, we first
performed a series of CBAs expressing individual rodent GABAAR
subunits or combinations thereof. The patient samples of CSF and
plasmapheresis eluate (PPE) containing polyclonal antibodies
showed predominantly an α1 reactivity. Additionally, they bound
very weakly to cells expressing subunit combinations of α2β3,
α5β3 (CSF and PPE), and β3γ2 (PPE only; Fig. 2 A and Fig. S3 A).
mAb stainings confirmed the α1 subunit as themain immunogenic
target of the GABAAR (Fig. 2 A and Fig. S3 A) and excluded binding
to α1–5-, β1–3-, or γ2-subunits for all further mAbs with anti-
neuronal reactivity (Fig. 2 A, exemplarily shown for #113-109).
Whereas GABAAR mAbs #113-101, #113-115, and #113-198 selec-
tively target α1, #113-201 additionally bound γ2 as an independent
target (Fig. 2 A). GABAAR reactivity of #113-175 is also α1 and
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γ2 mediated but requires their coexpression (Fig. 2 A and Fig. S3
A), suggesting that #113-175 recognizes a three-dimensional epi-
tope of α1γ2-containing GABAAR heteromers.
For the identification of the mAb with the strongest binding
to natively expressed GABAARs, we then quantified binding of
purified mAbs at serial dilutions to murine cerebellum (Fig. 2 B).
Binding curves were derived frommean fluorescence intensities
(MFIs) to quantify maximum intensity (MFImax) and concen-
trations at which 50% ofMFImax is reached (Half Max; Table S2).
#113-115 showed strongest reactivity (Fig. 2 B, red), as indicated
by lowest Half Max of 160 ng/ml, which was ∼40-fold higher
than that of the weakest binder #113-201 (Fig. 2 B, orange).
Models from four out of five mAbs displayed similar MFImax.
This indicates likewise similar available binding sites, which for
α1-selective mAbs are represented by the presence of two α1-
subunits and therefore two binding sites per heteropentameric
GABAAR. In contrast, the target epitope of #113-175 involves the
α1- and γ2-subunit and therefore can likely be present only once
per GABAAR. Consistently, mAb #113-175 reached a considerably
lower MFImax, but with a similar concentration dependency as
#113-115 (Fig. 2 B, purple). In a complementary assay using
flow cytometry, we found similar binding to HEK cells over-
expressing rat α1β3γ2 GABAAR for all five mAbs (Fig. S3, B–D
and F; and Table S2). In contrast, when using HEK cells over-
expressing human α1β3γ2 GABAAR, Half Max values were
similar for four out of five mAbs only and were ∼200-fold
lower for #113-201 (Fig. S3, E and G; and Table S2), indicating
preferential binding to the human receptor.
As GABAAR binding for all mAbs involves α1, we analyzed
whether target epitopes are identical or in close proximity in a
competition assay. GABAAR mAbs were fluorophore-coupled
and used for quantitative detection of binding to murine cere-
bellum. The binding of each fluorophore-coupled GABAAR mAb
was abrogated in the presence of its respective unlabeled mAb at
excess, but not when coapplied with nonreactive control mAb
#mGO53 (Fig. 2 C). Quantification of all possible pairings of
GABAAR mAbs revealed that certain mAbs can decrease the
binding of other GABAAR mAbs (Fig. 2 C, black tiles), suggesting
competition for overlapping target epitopes. In contrast, #113-
201 did not influence receptor binding of any other GABAAR
mAb. Interestingly, the binding signal of #113-101 was markedly
increased in the presence of unlabeled #113-115 (Fig. 2 C, yellow
tile) and similarly with #113-115 fragment antigen-binding (Fab)
fragments (Fig. S3 H). As #113-101 did not directly bind #113-115
(Fig. S3, I and J), this finding suggests conformational GABAAR
changes induced by #113-115 binding, leading to increased #113-
101 epitope accessibility in vitro.
mAb #113-115 selectively reduced GABAergic currents without
causing receptor internalization
Next, we explored the pathogenic relevance of single GABAAR
mAbs on GABAergic functions in vitro. We selected #113-115,
being the mAb with strongest binding to native GABAARs, and
#113-175, which depends on α1γ2 coexpression. In electrophys-
iological recordings from cultured autaptic neurons incubated
for 24 h with 1 µg/ml of #113-175, we observed no differences
Figure 1. Binding of human mAbs to GABAAR and other CNS targets. (A and B) Immunofluorescence stainings of human GABAAR mAb #113-115 (green) on
unfixed murine brain tissue, with binding to hippocampal neuropil. (B) Higher magnification of the hippocampal CA3 area showing the colocalization with a
commercial anti-GABAAR antibody (red; nuclei in blue). (C) Live-cell staining of GABAAR mAb #113-115 on cultured cortical rat neurons. (D and E) Immu-
nofluorescence staining on fixed cultured cortical rat neurons, with GABAAR mAb #113-115 (green) in D with clustered binding pattern along MAP2+ (red)
dendrites and in E colocalization with commercial antibodies against GABAAR (red) and the presynaptic marker vGAT (blue). (F–J) Immunofluorescence staining
of human GABAAR-negative mAbs (green; nuclei in blue) from encephalitis patient’s CSF repertoire with reactivity in variable distribution patterns on unfixed
murine brain sections, including binding to blood vessels (F), hippocampal neuropil (G), cell soma in corpus callosum (H), and cells of different cerebellar layers
(J and I). F shows a tile scan of a whole sagittal brain section. Inserts in H–J show mAb staining on fixed cultured neurons. All stainings were replicated at least
twice on tissue or neurons from two different animals. Scale bars indicate 100 µm in A and B, 20 µm in C–E, 100 µm in F–J, and 20 µm in inserts of F–J. GCL,
granule cell layer; MCL, molecular cell layer; MoDG, molecular layer of the dentate gyrus; neg. ctrl., negative control; PCL, Purkinje cell layer; rb, rabbit.
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with untreated and control conditions. In contrast, #113-115
led to reduced inhibitory postsynaptic signaling, as indicated
in lower amplitudes of evoked inhibitory postsynaptic cur-
rents (IPSCs; Fig. 3, A and C), in comparison with untreated
condition and with control mAb treatment (#113-115: 0.31 ±
0.09 SEM; untreated: 1 ± 0.12, P < 0.0001, Kruskal-Wallis,
Dunn’s post hoc; control: 0.91 ± 0.16, P = 0.0037). This effect
was GABA specific, as amplitudes of selective responses to
GABA (Fig. 3, B and D) were likewise reduced (#113-115: 0.55 ±
0.06; untreated: 1 ± 0.09, P = 0.0011; control: 1.02 ± 0.07, P =
0.0001), whereas responses to kainate and NMDA remained
unaffected (Fig. 3, E and F).
Previous studies using patients’ sera or CSF containing
GABAAR antibodies suggested receptor internalization as a
Figure 2. GABAAR subunit epitopes and mAb binding properties. (A) Immunofluorescence stainings as CBAs using COS7 cells overexpressing individual or
multiple GABAAR subunits (as illustrated in left column) to evaluate subunit-specific binding of patient’s polyclonal samples and derived recombinant mAbs
(red; nuclei in blue). Negative controls #mGO53 and #113-109 showed no binding. Underlined subunits were stained with subunit-specific commercial an-
tibodies (shown in green in image inserts). Note that β3 alone is expressed on the cell surface, but α1 alone is not (Ebert et al., 1999). (B) For relative
quantification of human GABAAR mAb binding to natively expressed receptors, the MFI was measured from binding in the granule cell layer of the murine
cerebellum. Representative images from #113-115 are shown in top row with IgG concentrations as indicated. Per condition, MFIs from 15 ROIs from three
independent experiments were used to fit nonlinear regression models of specific binding. Bars indicate mean ± SEM. (C) For analysis of competitive binding,
fluorophore-coupled GABAAR mAbs (detection mAbs) were stained on murine brain tissue in combination with an uncoupled mAb (competing mAb) in excess.
The degree of detection mAb labeling was between 7.2 (#113-115) and 17.5 (#113-198). Exemplary images from coupled #113-101 are shown in top row.
Quantified mean MFIs as relative values to noncompeting condition of the respective coupled mAb are shown as a heat map, each derived from 45 ROIs from
three independent experiments. Receptor binding competition is visualized in black and signal enhancement in yellow. Representative scale bars indicate
20 µm in A and 100 µm in B and C.
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pathogenic mechanism in GABAAR encephalitis. To examine
this mechanism at the level of mAbs, we quantified protein
levels from neuronal cultures after mAb incubation (Fig. S4, A–C;
and Fig. 3, G–J). The expression levels of GABAAR and control
protein glutamate receptor 1 (GluR1) were unaltered under mAb
treatment and control conditions, both in the total protein (Fig. 3, G
and H) and in the surface protein fractions (Fig. 3, I and J). Control
experiments ensured the presence and stability of mAbs after the
culture conditions (Fig. S4, D and E). These results were indepen-
dently confirmed using reader-based immunocytochemistry to
quantify surface GABAAR levels of neuronal cultures, which
displayed no changes between all groups (Fig. S4 F).
Cerebroventricular infusion of #113-115 IgG and Fab fragments
induced encephalopathic symptoms and increased mortality
The effects observed in vitro indicate direct pathogenicity of
antibody–antigen binding, independent of receptor internalization,
a mechanism related to bivalent antibody-mediated cross-linking
(Hughes et al., 2010). To explore the role of the antibody’s biva-
lence for its functionality, we generated and characterized a
Figure 3. mAb #113-115 selectively reduced GABAergic signaling in vitro, independent of receptor internalization. (A and B) Representative traces from
evoked (A) or GABA-dependent (B) currents of murine autaptic neurons after preincubation with indicated human mAb. (C–F) Amplitudes of evoked or
chemically induced responses (C) to GABA (D), kainite (E), or NMDA (F) of murine autaptic neurons after mAb preincubation as indicated (values normalized to
mean of untreated condition). Data were analyzed using Kruskal-Wallis, Dunn’s post hoc tests (**, P ≤ 0.01; ****, P ≤ 0.0001; or not shown when P > 0.05).
Each dot represents one neuron, n = 25 per condition. Bars indicate mean ± SEM. (G–J)Quantifications of the indicated total (G and H) and biotinylated surface
(I and J) proteins from cultured neocortical rat neurons as analyzed by Western blotting (values normalized to N-Cadherin expression and mean of untreated
condition). Each dot represents one preparation after mAb treatment, n = 11 per condition from four separate neuronal cultures. Bars indicate mean ± SEM.
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monovalent Fab fragment version of #113-115 lacking the fragment
crystallizable (Fc) domain (Fig. S5, A and B). Next, we used the
#113-115 IgG and Fab to assess whether they can similarly induce
pathogenic effects in vivo when applied in mice by continuous
cerebroventricular infusion via osmotic pumps.
Within a few days after implantation, six out of seven mice of
the #113-115 IgG high-dose (1.5 µg of IgG per hour) group and all
five mice of the #113-115 Fab high-dose group developed en-
cephalopathic symptoms compatible with impaired GABAergic
inhibition, including myoclonus, twitching, gait ataxia, and
circling (Video 1 and Table S3). In the #113-115 IgG low-dose
group (0.3 µg per hour) only two out of six mice developed
similar symptoms, which started later after pump implantation.
No disease symptoms were observed in the control mice after
mAb #mGO53 infusion. All symptomatic mice in the #113-115 IgG
high-dose and #113-115 Fab group died or had to be sacrificed
after reaching predefined humane endpoints, commonly status
epilepticus (Fig. 4 D and Table S3).
Extracted brains from #113-115–infused but not #mGO53-
infused mice revealed intense deposition of human IgG or Fab
in a characteristic GABAAR distribution pattern (Fig. 4, A–C),
indicating in vivo antigen binding. However, the levels of GA-
BAAR and control proteins from homogenized extracted brains
showed no differences between the groups (Fig. 4, E–H), con-
sistent with the in vitro data (Fig. 3, G–J; and Fig. S4 F).
GABAAR mAbs caused spontaneous seizures in vivo and
spontaneous epileptic activity ex vivo
The mAb-induced in vivo phenotype suggested hyperexcitabil-
ity and seizures. We used a wireless electroencephalography
(EEG) system to further evaluate the influence of GABAAR mAbs
on electric activity at lower concentrations not causing mortal-
ity. We examined 15 male Wistar P21 rats that received cere-
broventricular infusion of GABAAR mAbs or controls over 7 d
and were concurrently implanted with EEG transmitters to
record ictal events (Fig. 5 A). The EEG coastline length was
significantly higher in the GABAAR mAb–infused animals, in-
dicating increased epileptiform activity (Fig. 5 B). For the ap-
plication of #113-115 and also of α1γ2-dependent #113-175, this
correlated with an increase of ictal events as detected by the
automated seizure detection program (Fig. 5, C and D), including
Racine stage 5 seizures (Fig. S5 C and Video 2; Lüttjohann et al.,
2009). In a subgroup of three GABAARmAb–infused animals, we
performed prolonged EEG recordings over 21 d. Ictal events were
detected until the end of the recording period, although at a
lower level than during the infusion (Fig. S5 D), correlating also
with a peak in the postseizure behavioral battery (PSBB) score,
indicating the animals’ hyperexcitability and aggression (Fig. S5
E). The EEG of the GABAAR mAb animals showed significantly
higher power in all the power band ranges (Fig. 5 E).
After the completion of infusion with GABAAR or control
mAbs (days 7–8), acute sagittal brain slices were prepared for
local field potential recordings to assess for spontaneous epi-
leptic activity from electrodes placed in areas CA3 and CA1 of the
hippocampus. There were significantly higher numbers of spon-
taneous epileptic events during recordings from the GABAAR
mAb–infused animals at day 7/8 and at day 21 compared with
controls from day 7/8 (Fig. 5, F and G). This shows a preservation
of the prolonged epileptic activity seen in vivo from depth elec-
trode recordings of the GABAAR mAb–infused animals.
Figure 4. GABAAR IgG- and Fab-induced increased mortality. (A–C) Immunofluorescence stainings on brain sections from C57BL/6 mice after cere-
broventricular infusion (cv-inf.) of the indicated GABAAR or control mAbs over 14 d. Detection with anti-human Fc-specific antibody (red) or anti-human Fab-
specific antibody (green; insert in B) revealed characteristic hippocampal mAb deposition of #113-115 IgG (A) and #113-115 Fab (B). (C) Not seen in control
animals receiving control IgG (#mGO53). Representative scale bars indicate 100 µm. (D) Kaplan-Meier plot for survival of C57BL/6 mice after cerebroven-
tricular infusion over 14 d of indicated mAbs as IgG in high or low dose (1.5/0.3 µg IgG per hour) or as Fab in high dose. Survival was significantly different as
analyzed using log-rank Mantel-Cox (P ≤ 0.0001), followed by ANOVA, post hoc Tukey’s multiple comparisons (***, P ≤ 0.001; or not shown when P > 0.05; n =
5–7 animals per group). (E–H) Quantifications of the indicated total (E and F) and surface (G and H) proteins from murine brain homogenates after cere-
broventricular mAb infusion as analyzed by Western blotting and normalized to mean of control IgG group. Each dot represents one hemisphere, n = 10 per
condition. Bars indicate mean ± SEM.
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Discussion
Here, we provide insight into the CSF antibody repertoire of
acute GABAAR encephalitis. So far, only a few studies have in-
vestigated patient-derived mAbs from different forms of
autoantibody-mediated encephalitis. These reports included
either only a single target-specific mAb (Brändle et al., 2021;
Malviya et al., 2017) or only mAbs that were isolated from the
periphery (Ramberger et al., 2020; Sharma et al., 2018) and also
did not observe a phenotype mimicking the patients’ key
symptoms (Malviya et al., 2017; Ramberger et al., 2020; Sharma
Figure 5. GABAAR mAbs caused spontaneous seizures in vivo and spontaneous epileptic activity ex vivo. (A) Representative EEG of an ictal event
recorded from a CA3 depth electrode in a Wistar rat receiving GABAAR mAb infusion. (B) Comparison of hourly averages of coastline length between GABAAR
mAb (#113-115, n = 3; #113-175, n = 3) and control (n = 6) infused animals, analyzed using Mann-Whitney (***, P ≤ 0.001; n = 900–905 average values per
group). Horizontal lines indicate mean and quartiles. (C) Comparison of the hourly ictal event counts between animals during infusion with GABAAR mAb or
control as analyzed from Neuroarchiver seizure detection software and using Mann-Whitney (****, P ≤ 0.0001). Animal numbers as in B, n = 120 events per
group. Bars indicate mean ± SEM. (D) Distribution of the detected ictal event over time. (E) Comparison of hourly EEG power averages throughout 7-d re-
cordings during GABAAR mAb or control infusion, analyzed using Mann-Whitney (**, P ≤ 0.01; ****, P ≤ 0.0001). Animal numbers as in B, n = 899–900 average
values per group. Bars indicate mean + SEM. (F) Local field potential recording from the CA3 region in a sagittal brain slice from a rat after GABAAR mAb
infusion (upper trace) showing spontaneous ictal activity ex vivo, not seen in controls (lower trace). (G) Comparison of interevent intervals of spontaneous ictal
activity from postmortem acute brain slice recordings from rats after cerebroventricular antibody infusion over 7 d. Recordings from GABAAR mAb–exposed
brains are from day 7/8 (#113-115, n = 3; #113-175, n = 3) or day 21 after beginning of infusion and from day 7 of control exposed brains (n = 6), analyzed using
Mann-Whitney (****, P ≤ 0.0001; n = 44–10,302 intervals per group). Bars indicate geometric mean ± SD.
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et al., 2018) or completely lacked in vivo data (Brändle et al.,
2021; Kornau et al., 2020; Kreye et al., 2016). In contrast, we
here present a systematic characterization of the functional
role of patient-derived disease-specific anti-neuronal autoanti-
bodies in GABAAR encephalitis. Using a recombinant single-cell
cloning approach, we isolated five monoclonal human GABAAR
autoantibodies and comprehensively showed that they recognized
GABAARs in vitro and in vivo, induced electrophysiological effects
independent of receptor internalization, and caused a severe en-
cephalitic phenotype in two rodent models. Unlike human serum
or CSF containing polyclonal autoantibodies against GABAAR and
potentially other targets, themAbs allowed the detailed analysis of
antibody sequences, epitope mapping, and autoantibody-specific
pathogenic functional effects, resulting in a number of novel
findings.
The identified GABAAR mAbs revealed typical indicators of
affinity maturation, similar to LGI1 mAbs (Kornau et al., 2020;
Ramberger et al., 2020) and in contrast to NMDARmAbs that we
and others have reported with low SHM numbers (Kreye et al.,
2016; Malviya et al., 2017) or even in germline configuration
(Wenke et al., 2019). The main epitope of all five GABAAR mAbs
was the α1 receptor subunit, as suggested from previous studies
using polyclonal patient samples (Petit-Pedrol et al., 2014;
Pettingill et al., 2015) and by one mAb that has recently been
reported (Brändle et al., 2021). However, in our study one mAb
independently codetected the γ2-subunit, and another bound to
a shared epitope requiring both α1 and γ2 receptor subunits.
Importantly, the latter mAb therefore cannot be detected in
current commercial CBAs that use α1β3 GABAAR, with the po-
tential implication that routine diagnostics in acute encephalitis
may underestimate disease-relevant GABAAR antibody titers or
even overlook affected patients, in case patients harbor only
antibodies directed to γ2 receptor subunits in their polyclonal
antibody response. The target epitopes of some GABAAR mAbs
were identical or in close proximity, as shown in our antibody
competition assays and indicated from prior experiments with
the limitations of CSF polyclonality (Petit-Pedrol et al., 2014).
Conversely, the presence of mAb #113-115 did not reduce but
enhanced binding of mAb #113-101 to the GABAAR. This suggests
a direct conformational change of the receptor upon mAb
binding, thus potentially adding a new pathogenic principle to
the complexity of antibody-induced effects in autoimmune en-
cephalitis. Likewise, conformational effects of disease-relevant
mAbs may in some cases stabilize the receptor in a specific ac-
tivation state, similar to nanobodies that, in this way, allowed
first structure crystallography of G protein–coupled receptors
complexed with their G protein (Rasmussen et al., 2011).
Our functional investigations in vitro and in vivo showed the
pathogenicity of the two selected GABAAR mAbs #113-115 and
α1γ2-dependent #113-175. Cerebroventricular infusion of both
mAbs induced a severe phenotype with seizures and increased
mortality, similar to encephalitis patients and in linewith epileptic
encephalopathies in GABAAR mutation carriers (Hernandez et al.,
2019; Lachance-Touchette et al., 2010; Maljevic et al., 2006;
Wallace et al., 2001). However, electrophysiological recordings
from autaptic neuronal cultures revealed a reduction of GA-
BAergic currents for mAb #113-115, but not for α1γ2-dependent
#113-175. The observed increase of epileptiform activity in vivo
after #113-175 infusionmay, among other reasons, be mediated via
yet unknown factor(s) that are not present in vitro, via receptor
modulation (e.g., by affecting the access of benzodiazepine-like
compounds) or via network effects, and thus may not be detect-
able in all cases in the autaptic in vitro model. For both mAbs, we
did not observe receptor internalization, a previously highlighted
mechanism (Ohkawa et al., 2014; Pettingill et al., 2015). Possible
explanations for the different findings include the use of patient
samples containing polyclonal antibodies with undetermined
additional specificities in previous studies and the presence of
GABAAR β3-subunit antibodies not assessed in our study. For
#113-115, the electrophysiological findings and missing internali-
zation together with the suggested change of receptor conforma-
tion indicate direct functional effects upon mAb binding. Possible
mechanisms include stabilization of the receptor in a desensitized
state similar to the GABAAR agonist benzamidine (Miller and
Aricescu, 2014), allosteric modulation of the physiological GABA-
binding affinity and/or neurotransmission efficacy, and orthos-
teric GABA antagonism. Additionally, redistribution of GABAAR
between synaptic and extrasynaptic locations may further con-
tribute to GABAergic dysfunction, as likewise reported from
NMDAR autoantibodies (Jézéquel et al., 2017; Ladépêche et al.,
2018). Pathogenic mechanisms beyond internalization alone had
been suggested by previous results (Ohkawa et al., 2014), showing
a frequency reduction of IPSCs after GABAAR antibody applica-
tion. Furthermore, our additional in vivo experiments using
monovalent GABAAR Fab fragments not only replicated the severe
mAb-induced phenotype but also supported the concept of direct
effects of autoantibody–autoantigen binding, similar to recent
studies in which polyclonal Fab fragment preparations of glycine
receptor autoantibodies specifically reduced glycinergic currents
(Crisp et al., 2019). In both cases, Fab fragment experiments prove
mAb pathogenicity independent of the integrity of the whole
antibody, thereby excluding the dependency of the antibody’s
bivalence and Fc-mediated effector functions such as antibody-
dependent cell-mediated cytotoxicity, antibody-dependent cellu-
lar phagocytosis, and complement-dependent cytotoxicity.
GABAAR encephalitis leads to frequent seizures, including
epilepsia partialis continua and treatment-refractory status ep-
ilepticus (Petit-Pedrol et al., 2014; Spatola et al., 2017), which
was the predominant phenotype also in our animal models.
Future studies should compare whether the intrathecal appli-
cation into rodents of polyclonal CSF from patients of a larger
cohort induces similar effects. Here, using wireless EEG in living
animals, we could quantify epileptiform activity. Ictal events
peaked under the mAb delivery and remained until the end of
the recording period, 14 d after termination of the infusion. Such
persistence has not been observed in NMDAR encephalitis
models, where cognitive changes were reversible after 10 d
(Malviya et al., 2017; Planagumà et al., 2015). Extendedmeasures
revealed higher coastline length (Jones and Heinemann, 1988)
and increased power in the lower frequency range (1–4 Hz),
consistent with EEG changes in human encephalitis patients
(Symmonds et al., 2018). Interestingly, in a pharmacologically
induced rodent model of status epilepticus, spontaneous sei-
zures were also associated with increased γ, θ, and Δ powers in
Kreye et al. Journal of Experimental Medicine 8 of 15
Human monoclonal GABAA receptor antibodies https://doi.org/10.1084/jem.20210012
the power spectrum, similar to our GABAAR mAb model
(Puttachary et al., 2015).
Similar to our findings in the related NMDAR encephalitis
(Kreye et al., 2016), we found a broad spectrum of CNS auto-
reactivity beyond GABAARs. These mAbs were reactive to sur-
face and intracellular epitopes on neurons, endothelium, and
choroid plexus. For example, we identified one anti–Homer-3
antibody, a known target protein in some patients with auto-
immune cerebellitis and ataxia (Höftberger et al., 2013). Ongoing
attempts to identify other auto-antigens using immunoprecipi-
tation/mass spectrometry, phage display, and protein arrays
followed by animal experiments with single mAbs or mAb combi-
nations will likely disclose their relevance for additional functional
effects, the clinical phenotype, and their potential as diagnostic
markers. It is tempting to speculate that the diverse non-GABAAR
reactivity against choroid plexus or blood vessels (e.g., mAb #113-
201) may contribute to blood-brain barrier dysfunction and thus
facilitate the entrance of further antibodies and immune cells into
the CNS, similar to the role of glucose regulatory protein 78 auto-
antibodies in neuromyelitis optica (Shimizu et al., 2017).
The present study confirmed the importance of isolation and
detailed characterization of disease-specific human mAbs from
the CSF of patients with encephalitis to foster the comprehen-
sive understanding of humoral CNS autoimmunity. Patient-
derived recombinant mAbs represent a useful research tool for
multiple purposes and thereby allow the detailed investigation
of disease mechanisms and the translation into animal models to
recapitulate the clinical phenotype. Most importantly though,
retracing the molecular mechanisms of human antibody path-
ogenicity will provide a refined biological view on some im-
portant clinical conditions, such as isolated psychosis or
catatonia, which can occur with GABAAR antibodies (Pettingill
et al., 2015; Pollak et al., 2020). This knowledge will help to
reduce the stigmatization associated with such psychiatric
conditions by understanding them as autoimmune disorders
that may require appropriate immunotherapy as a causative
treatment in addition to antipsychotics or psychotherapy. Si-
multaneously, the mAbs are the starting point for the devel-
opment of novel diagnostics and highly selective immunotherapies




The index patients’ parents have given written informed con-
sent, and analyses were approved by the Charité University
Hospital Institutional Review Board.
4 ml of CSF was collected during the acute phase of en-
cephalitis (Nikolaus et al., 2018) and immediately processed for
cell pellet cryopreservation, therefore centrifuged for 10min at 400×
g, with supernatant stored at −80°C and the pellet resuspended in
500 µl of 10% dimethyl sulfoxide, 45% fetal calf serum, 45% RPMI
mediumbefore freezing at−80°C. PPEwas collected 6 d after lumbar
puncture and stored at −80°C.
We used fluorescence-activated cell sorting to isolate single
CD138+ ASCs, CD20+CD27+ MBCs, and CD20+CD27− NMBCs from
preselected viable CD3−CD14−CD16−DAPI− lymphocytes into
96-well PCR plates. The following antibodies were applied:
anti–CD3-FITC (1:25; Miltenyi Biotec; #130-098-162), anti–CD14-
FITC (1:25; Miltenyi Biotec; #130-098-063), anti–CD16-FITC (1:25;
Miltenyi Biotec; #130-098-099), anti–CD20-PerCP-Vio700
(1:50; Miltenyi Biotec; #130-100-435), anti–CD27-APC-Vio770
(1:12.5; Miltenyi Biotec; #130-098-605), and anti–CD138-PE
(1:50; Miltenyi; #130-098-122).
Generation of recombinant human mAbs
From single-cell cDNA Ig, genes encoding for variable domains
of heavy and light chains were amplified, sequenced, and cloned
into expression vectors containing the respective constant Ig
domains. Sequence analysis data were confirmed by novel cus-
tom BASE software (Reincke et al., 2020). HEK cells (HEK293T)
were transiently transfected with an Ig vector pair, mAb con-
taining supernatant was harvested, and Ig concentrations were
determined, all following our established protocols (Kornau
et al., 2020; Kreye et al., 2016).
For reactivity screenings, supernatants were used if con-
centration was above 2 µg/ml. For detailed characterization of
reactivity probabilities and functional assays, cell supernatants
were purified using Protein G Sepharose beads, as described
before (Kreye et al., 2016). For Fab fragment synthesis (inVivo
BioTech), the IgG1 heavy chain vector was modified by the de-
letion of the part encoding for the Fc domains CH2 and CH3 in
exchange for a FLAG-Tag and a His-Tag following the amino
acids PKSCDKTH of the hinge region. Fab fragments were pu-
rified using immobilized metal affinity chromatography.
Primary neocortical cell cultures
Primary P0-P2 neocortical cultures were prepared from WT
Wistar rats, as previously described (Turko et al., 2019). Briefly,
dissected neocortex tissue was dissociated with Papain for
25 min (1.5 mg/ml; Merck) before trituration in BSA (10 mg/ml;
Merck). Cells were then resuspended in Neurobasal A medium
(supplemented with 1× B27, 1× Glutamax, and 100 U/ml
Penicillin-Streptomycin; Thermo Fisher Scientific). Dissociated
cells were grown in either 24-well or 6-well cell culture plates
coated for 1 h with poly-L-lysine hydrobromide (20 µg/ml;
Merck). For imaging with the luminescence plate reader, cells
were plated in 500-µl droplets at 400 cells/µl (total: 2 × 105
cells per well of a 24-well plate). For Western blot analysis, cells
were plated in 2-ml droplets at 500 cells/µl (total: 1 × 106 cells
per well of a 6-well plate). Cultures were grown in humidified
conditions at 37°C and 5% CO2. Cells were cultured until
20–22 d in vitro (DIV) before antibody treatment or fixation.
Immunohistochemistry
For reactivity screening, recombinant mAbs were stained on 20-
µm sagittal unfixed mouse brain sections mounted on glass slides.
After thawing, tissue was rinsed with PBS, and then blocking
solution (PBS supplemented with 2% BSA [Roth] and 5% Normal
Goat Serum [Abcam]) was applied for 1 h at room temperature. As
primary antibodies, undiluted HEK293T cell supernatants con-
taining recombinant mAbs were incubated overnight at 4°C. After
washing three times with PBS, Alexa Fluor 488–conjugated goat
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anti-human IgG (1:1,000; Dianova; #109-545-003) diluted in
blocking solution was added for 2 h at room temperature, before
an additional three-time washing and mounting using DAPI-
containing Fluoroshield.
For costainings (Fig. 1, B–E; and Fig. S2, A–D), purified re-
combinant human mAbs were used at 5 µg/ml, and tissue was
fixedwith 4% paraformaldehyde (PFA) and stained following the
same protocol, but using blocking solution supplemented with
0.1% Triton X-100 (Chemsolute). For costainings, commercial
antibodies rabbit anti–GABAAR α1 (1:250; Abcam; #ab33299),
guinea pig anti-VGAT (1:500; Synaptic Systems; #131004),
chicken anti-MAP2 (1:1,000; Thermo Fisher Scientific; #PA1-
16751), rabbit anti-MAP2 (1:1,000;Merck; #AB5622), Alexa Fluor
568–conjugated goat anti-chicken IgG (1:500; Invitrogen;
#AB_2534098), Alexa Fluor 647–conjugated goat anti–guinea
pig IgG (1:1,000; Invitrogen; #A21450), and Alexa Fluor 594–
conjugated goat anti-rabbit IgG (1:1,000; Dianova; #111-585-003)
were used, and stainings were examined under an inverted
fluorescence microscope (Olympus CKX41, Leica DMI6000) or
for confocal and large-scale tiling images taken with a cooled
electron multiplying charge coupled device camera (Rolera-MGi
PLUS, QImaging). For β-subunit stainings (Fig. S2, F–H), unfixed
murine brain sections and the commercial antibodies guinea pig
anti–GABAAR-β1 (1:500; Synaptic Systems; #224705), guinea
pig anti–GABAAR-β2 (1:500; Synaptic Systems; #224805), and
rabbit anti–GABAAR-β3 (1:500; Synaptic Systems; #224403)
were used.
CBAs
HEK293T cells were cultured on poly-L-lysine–coated cover-
slips, transiently cotransfected with plasmids (kindly provided
by Prof. Kneussel from the Center of Molecular Neurobiology in
Hamburg, Germany) to express rat α1β3 or α1β3γ2 GABAAR, and
48 h later used for live-cell immunostainings following our de-
scribed protocol, with reduced incubation time for primary
antibodies to 1 h at room temperature followed by PFA fixation.
For neuronal live-cell stainings, DIV 20–22 live WT neocor-
tical rat neurons were stained with human mAbs for 30 min in a
cell culture incubator at 37°C and 5% CO2, then washed once
before PFA fixation and secondary antibody application as above.
For neuronal costainings, cultured neurons were washed and
then first fixed with PFA, before application of blocking solution
supplemented with 0.1% Triton X-100 for permeabilization fol-
lowed by costaining procedures as described above.
GABAAR-negative mAbs with intense tissue reactivity were
screened for established neural antigens using commercial panel
tests (Euroimmun AG).
Polyreactivity ELISA
Antibodies were tested for polyreactivity by ELISA as previously
described (Tiller et al., 2008;Wardemann et al., 2003). High-protein
binding plates were coated overnight at room temperature with
six distinct antigens: 10 µg/ml calf thymus double-stranded DNA
(Sigma; #D8515), 10 µg/ml single-stranded DNA prepared from
double-stranded DNA (heated at 95°C for 30 min, immediately
aliquoted, and frozen at −20°C), 10 µg/ml LPS from Escherichia
coli (Sigma; #L2637), 10 µg/ml KLH (Sigma; #H8283), 10 µg/ml
Cardiolipin (Sigma; #C0563), and 5 µg/ml human insulin
(Sigma; I9278). Plates were washed, then blocked with PBS
supplemented with 0.05% Tween and 1 mM EDTA before
addition of mAbs diluted in DMEM (GIBCO BRL; #31331093)
supplemented with 1% Nutridoma-SP (Roche; #11011375001).
Plates were developed with HRP-labeled goat anti-human IgG
Fc antibody (1:5,000; Dianova; #109-035-098) and 1-Step Ul-
tra TMB ELISA Substrate Solution (Thermo Fisher Scientific;
#34029) and stopped with 2 M sulfuric acid. In all assays,
strongly polyreactive ED38 (Meffre et al., 2004) and weakly
polyreactive eiJB40 (Wardemann et al., 2003) were used as
positive controls and mGO53 as a negative control. The
threshold for positive binding was calculated for each antigen
separately as the OD450 subtracted by two SDs of eiJB40.
GABAAR subunit reactivity screening
Cell-based binding assay for GABAAR was described previously
(Ohkawa et al., 2014). In this study, we additionally cloned
cDNAs of rat GABAAR α3 (NM_017069), α4 (NM_080587), and
β2 (NM_012957) from rat brain total RNA by RT-PCR. COS7 cells
were transfected with the indicated GABAAR subunits. At 24 h
after transfection, the cells were fixed with 2% PFA at room
temperature for 20min and blocked with PBS containing 10mg/ml
BSA for 15min. The fixed cells were incubatedwith patient-derived
mAbs (5 µg/ml) followed by staining with the Cy3-conjugated
secondary antibody. Then, the cells were permeabilized with 0.1%
Triton X-100 for 10 min, blocked with PBS containing 10 mg/ml
BSA, and incubated with antibodies to individual GABAAR subunits
(underlined subunit in the illustration of Fig. 2 A), followed by
staining with the Alexa Fluor 488–conjugated secondary antibody.
We confirmed that any antibodies did not bind to untransfected
cells that did not express the GABAAR subunits through dis-
tinguishing untransfected cells with Hoechst dye (33342; Thermo
Fisher Scientific) nucleic acid staining. Imageswere capturedwith a
system (LSM5 Exciter; Carl Zeiss) equipped with a Plan Apochro-
mat 63×/1.40 numerical aperture oil immersion objective lens.
The antibodies used in this screening included rabbit polyclo-
nal antibodies to GABAAR α2 (1:250; Rockland Immunochemicals,
Inc.; #600-401-D45), α3 (1:250, extracellular epitope; Synaptic
Systems; #224 303), α5 (1:250; Millipore; #AB9678), β3 (1:250;
Abcam; #ab4046), and γ2 (1:250, extracellular epitope; Synaptic
Systems; #224 003); guinea pig polyclonal antibodies to GABAA
receptor β2 (1:250; Synaptic Systems; #224 805); andmousemAbs
to GABAA receptor α1 (1:250; NeuroMab; #75-136), β1 (1:250;
NeuroMab; #75-137), and α4 (1:250; NeuroMab; #73–383).
The identities of human and rat GABAAR α1-, α2-, α3-, α4-,
α5-, β1-, β2-, β3-, and γ2-subunits in their amino acid sequence
are 100%, 97%, 95%, 89%, 93%, 98%, 99%, 97%, and 99%, respec-
tively; that of the human and mouse γ2-subunit is 99%.
Quantification of relative binding strength on murine
brain sections
Following the protocol above, serial dilutions of purified GA-
BAAR mAbs from 50 to 0.002 µg/ml were used for staining of
adjacent unfixed murine brain sections. Cerebellar images were
recorded with identical settings and analyzed using ImageJ
software, version 1.51n (developed by the National Institutes of
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Health). From each image, the MFI was determined from five
random regions of interest (ROIs) within the granular cell layer,
secondary antibody MFI was subtracted as background, and
resulting MFI values were scaled to the average MFI values from
all five GABAAR mAbs at 20 µg/ml (Wenke et al., 2019). Non-
linear regression models [MFI = MFImax * IgG concentration/
(Half Max + IgG concentration)] under settings for one site-
specific binding were generated using GraphPad Prism 8
(GraphPad Software Inc.).
Quantification of relative binding strength via flow cytometry
Following our established protocol (Ly et al., 2018), HEK293T cells
were transiently cotransfected with plasmids encoding for rat or
human α1-, β3-, and γ2-subunits of GABAAR and enhanced GFP
(EGFP) or EGFP only and then stained with serial dilutions of
purified mAbs. From live single cells with top 30% protein ex-
pression (evaluated by EGFP signal), the MFI of the Alexa Fluor
647–conjugated goat anti-human IgG (1:400; Life Technologies)
was calculated, and nonlinear regressionmodels were determined
as above.
Competition assay
400 µg of purified GABAAR mAbs was concentrated to a volume
of 100 µl using Amicon Ultra 100-kD columns (Merck) and then
incubated with 40 µg CruzFluor 488 (CF488) succinimidyl ester
(Santa Cruz Biotechnology) for 1 h under rotation in the dark.
Unbound fluorophores were washed out using Amicon Ultra
100-kD columns. IgG concentrations were determined using an
IgG ELISA. The degree of labeling (DOL) was calculated from
spectrophotometer readings according to the manufacturer’s
instructions and by using the following formula (with εIgG =
210,000 cm−1 M−1, εCF488 = cm−1 M−1, Correction Factor280 = 0.11):
DOL  [Abs495 × εIgG] /
[εCF488 × (Abs280−
Correction Factor280 × Abs495)]
(ATT Bioquest, 2021). The degrees of labeling obtained for the
CF488-coupled mAbs were 10.9 for #113-101, 7.2 for #113-115,
10.8 for #113-175, and 17.5 for #113-198 and #113-201. CF488-
coupled GABAAR mAbs were used in serial dilutions to stain
unfixed mouse sections, and binding was quantified by MFI
quantification of CF488 signals to determine individual con-
centrations for eachmAb, yielding intensities between detection
threshold and signal saturation. At these concentrations (0.4 µg/
ml for #113-115, 4 µg/ml for all others), CF488-coupled mAbs
were costained with uncoupled mAbs in excess at 50 µg/ml, and
MFIs were quantified and compared with single-staining MFIs.
Quantification of surface protein expression from
cultured neurons
To quantify expression of cell surface proteins, we performed
state-of-the art biotinylation assays (Hughes et al., 2010;
Ohkawa et al., 2014). In brief, DIV 20–22 rat neocortical neurons
were treated with 5 µg/ml of GABAAR or control mAb in culture
medium for 16–18 h. Neurons were washed, then incubated with
EZ-Link Sulfo-NHS-SS-Biotin (Thermo Fisher Scientific) for
30 min at 4°C. After quenching unbound biotin, scratched
neurons were lysed via sonification in RIPA buffer (150 mM
NaCl, 1 mMEDTA, 100mMTris HCl, 1% Triton X-100, 1% sodium
deoxycholate, and 0.1% SDS, pH 7.4, supplementedwith protease
inhibitor cocktail cOmplete Mini [Roche]) for 1 h at 4°C. Lysates
were cleared of debris by centrifugation at 20,000× g for
20 min. The supernatant (whole protein fraction) was incubated
with NeutrAvidin UltraLink beads (Thermo Fisher Scientific)
for 3 h at 4°C, then eluted (surface proteins fraction). Samples
were separated on an 8% gel using SDS-PAGE and analyzed by
Western blotting. Images were recorded luminescence based on
ImageQuant LAS 4000 mini and quantified using ImageQuant
TL software (GE Healthcare; version 8.2).
For immunohistochemistry-based receptor quantification,
we used DIV 20–22 rat neocortical neurons cultured in 24-well
plates and applied identical mAb treatments as above. Neurons
were stained as live cells with rabbit anti–GABAAR α1 antibody
(1:1,000; Abcam; #ab33299), then washed and fixed with 4% PFA
before application of IRDye 680RD goat anti-rabbit IgG sec-
ondary antibody (1:2,000; LI-COR; #925-68071) for 2 h at room
temperature and a final washing with PBS. Plates were recorded
in an Odyssey CLx Imaging System (LI-COR) under high-quality
resolution settings and analyzed using Image Studio Ver. 5.2 (LI-
COR). For each well from a 2,000-pixel–sized circular ROI, the
total pixel intensities were summed, background signals from
control wells without primary antibody were subtracted, and
these values were scaled to the mean from all wells under the
untreated condition of this plate.
Autaptic neurons and electrophysiological recordings
Autaptic murine striatal neurons (DIV 15–18) were selected for
IPSC recordings as these provide a homogeneous composition of
inhibitory neurons, although with the limitation of the lack of op-
portunity to measure excitatory postsynaptic currents as controls.
Autapses were incubated with 1 µg/ml human GABAAR mAb or
control antibody (anti-CD52; Bio-Rad; #HCA175) at 37°C for 24 h.
Data collection from four independent cultures was performed as
previously described (Zimmermann et al., 2015) with the following
alterations. Cells were recorded in standard intra- and extracellular
solutions, except for chemically induced NMDA responses, mea-
sured in extracellular solution containing 0mMofMg2+, 0.2mMof
CaCl2, and 10 µM of glycine. All drugs were bath applied for 1 s
except for GABA, which was applied for 3 s. Currents were nor-
malized per culture to the mean of untreated recordings.
Animals
All animal experiments were performed according to the AR-
RIVE guidelines and were approved by the Thuringian state
authorities (authorization UKJ-17-053) and UK home office
guidelines. Male C57BL/6 mice were used at an age of 13–14 wk
and male Wistar rats at postnatal age of 21 d (weighing 50–58 g).
Animals were housed in temperature- and humidity-controlled
conditions on a 12-h/12-h dark/light cycle and provided with
food and water ad libitum.
Intrathecal osmotic pump infusions
An investigator not involved in the animal experiments random-
ized mice for assignment to the respective treatment. Animals
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received mAb #113-115 either as IgG (high-dose group: 500 µg
over 14 d, 1.5 µg/h, n = 7; low-dose group: 0.3 µg/h, n = 6) or as
Fab fragment (equimolar [16.5 M] to 1.5 µg/h of IgG, n = 5) or
control mAb mGO53 as IgG (1.5 µg/h, n = 5).
Cerebroventricular infusion with GABAAR mAb or control
was performed using osmotic pumps (Alzet; model 1002), which
were loaded the day before surgery. The following character-
istics were used as previously reported (Petit-Pedrol et al., 2018;
Planagumà et al., 2016): volume 100 µl, flow rate 0.25 µl/h, and
duration 14 d. For surgery, mice were placed in a stereotaxic
frame, and a bilateral cannula (PlasticsOne; model 3280PD-2.0/
SP) was inserted into the ventricles (coordinates: 0.2 mm pos-
terior and ±1.00 mm lateral from bregma, depth 2.2 mm). Each
arm of the cannula was connected to one osmotic pump, which
was subcutaneously implanted on the back of the mice (two
pumps per animal). After surgery, mice were kept single caged
and were monitored daily to assess symptoms and survival and
were videotaped at representative time points. Mice were
sacrificed at day 15. Brain tissue was obtained and frozen in
2-methylbutane.
Quantification of receptor expression from animals treated via
osmotic pumps
For Western blot analysis, cryopreserved brain hemispheres
from treated mice were thawed and dounced in homogenization
buffer (1X PBS, 0.32 M Sucrose, 10 mM Hepes, pH 7.4, 2 mM
EDTA, and 1.6 mM PMSF, supplemented with protease inhibitor
cocktail cOmplete Mini). Samples were centrifuged at 1,000× g
for 10 min. The supernatants (total cell fraction) were recen-
trifuged at 10,000× g for 15 min, and the obtained supernatant
was finally ultracentrifuged at 100,000× g for 60 min. These
pellets were suspended in sample buffer (membrane fraction),
separated using SDS-PAGE, and analyzed by Western blotting
as above.
Rat surgery: Placement of ventricular catheters, osmotic
pumps, and wireless EEG transmitters
Osmotic pumps (Alzet; model 1007D) were used for cere-
broventricular infusion of GABAAR mAbs (volume 100 µl, flow
rate 0.5 µl/h, and duration 7 d). The day before surgery, two
osmotic pumps per animal were prepared by loading with either
one mAb or IgG derived from one healthy human aged 35 yr. As
the initial dose of GABAAR #113-115 led to animal death through
status epilepticus, applied amounts were reduced in subsequent
animals, resulting in ranges from 40 to 120 µg human mAb
(#113-115: n = 6, #113-175: n = 3, #mGO53: n = 4) or 6 mg of
polyclonal human IgG (n = 2) per animal. The loaded pumps
were then connected to polyethylene tubing 69-mm × 1.14-mm
diameter (PlasticsOne; C312VT) and a double osmotic pump
connector intraventricular cannula (PlasticsOne; 328OPD-3.0/
SPC). Pumpswere left overnight in sterile saline solution at 37°C.
The next day, under isoflurane anesthesia, rats were placed
in a stereotaxic frame for surgery. The osmotic pumps were
placed subcutaneously, and the attached cannula was inserted into
the lateral ventricles (1.5 mm lateral, 0.6 mm caudal). A subcu-
taneous pocket was formed over the right flankwith a single skin
incision and blunt tissue dissection for the transmitter (OpenSource
Instruments [OSI]; A3028B-DD subcutaneous transmitters, 90-mm
leads), and depth electrode (OSI; W-Electrode [SCE-W]) was
placed in the left hippocampus (CA3, 3.5 mm lateral, 3.6 mm
caudal, depth 2.3 mm) with reference electrode implanted in the
contralateral skull (3.5 mm lateral, 3.6 mm caudal). The cannula
and skull electrodes were secured with dental cement as previ-
ously described (Wright et al., 2015). Placement of catheters and
electrodes was assessed postmortem during preparation of brain
slices for electrophysiology and immunostaining.
Collection and analysis of EEG data
A custom-built Faraday cage with aerial was used to collect and
record EEG data. Transmitter signals were continuously re-
corded in animals while freely moving using Neuroarchiver
software (OSI) and analyzed as previously described (Wright
et al., 2015; Wykes et al., 2012). In brief, the EEG coastline
length was measured as the cumulative absolute difference in
voltage between consecutive data points (Korn et al., 1987). For
automated ictal event detection, video-EEG matching was used
to identify ictal EEG events. The Event Classifier (OSI) was then
used to classify 1-s segments of EEG according to several metrics,
enabling similar events to cluster together when plotted ac-
cording to metrics. This generated a library of ictal events that
allowed fast identification of abnormal EEG events by automated
comparison to the library (http://www.opensourceinstruments.
com/Electronics/A3018/Seizure_Detection.html). Powerband
analysis was performed using a custom-designed macro.
Behavioral tests
The PSBB was used to monitor long-term behavioral changes
during and after the GABAAR antibody infusion (two tests were
performed each week for the 3-wk recording period in n = 3
animals). The behavioral task consists of two simple and non-
stressful tasks (i.e., touch and pickup tasks). If the product of
these scores is >10, the animals are highly likely to have devel-
oped hyperexcitability and aggression; these measures strongly
correlate with the development of spontaneous recurrent sei-
zures (Modebadze et al., 2016).
Local field potential recordings
At the end of the recording period, 450-µm brain slices were
prepared from the GABAAR and control mAb-infused rats and
used for hippocampal local field potential recordings as previ-
ously described (Johnson et al., 2017; Modebadze et al., 2016).
Local field potential recordings were assessed using Spike2
software (CED) for spontaneous epileptiform activity. Spike2
was used to calculate the root mean square amplitude of each
recording. Epileptiform activity was classified as an event when
it displayed amplitudes greater than fourfold the root mean
square amplitude, providing the event count, while the time
difference between these events provided the interevent inter-
val.Measurements are expressed asmedian, interquartile range,
and min-max values.
Statistical analysis
All statistical analyses were conducted using GraphPad Prism 8
(GraphPad Software Inc.). For sequence analysis, numbers of
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somatic hypermutations were compared using an ordinary one-
way ANOVA test followed by post hoc Tukey’s multiple compar-
isons tests. Amplitudes from autaptic neuron recordings were
tested using Kruskal-Wallis, Dunn’s post hoc tests. Protein expres-
sion quantifications from Western blotting and immunohisto-
chemistry data were analyzed with ordinary one-way ANOVA tests
followed by post hoc Tukey’s multiple comparisons tests. Kaplan-
Meier survival analysis was analyzed by log-rank (Mantel-Cox)
test followed by ANOVA with post hoc Tukey’s multiple com-
parisons tests. Coastline length measurements, ictal event counts,
and power averages from in vivo EEG recordings and interevent
intervals of spontaneous ictal activity from postmortem acute
brain slice recordings were analyzed using Mann-Whitney tests.
Online supplemental material
Fig. S1 supplements Fig. 1 and shows the identification of GA-
BAAR mAbs, their Ig sequence features, and polyreactivity data.
Fig. S2 supplements Fig. 1 and shows further immunofluores-
cence stainings of patient-derived and commercial GABAAR
mAbs on murine brain tissue. Fig. S3 supplements Fig. 2 and
shows specificity and binding strength data of GABAAR mAbs.
Fig. S4 supplements Fig. 3 and provides data from control ex-
periments for the quantification of protein expression from
cultured neurons treated with GABAAR mAbs. Fig. S5 supple-
ments Fig. 4 and Fig. 5 and provides the characterization of
GABAAR Fab #113-115 and animal data from prolonged EEG re-
cordings and behavioral testing after cerebroventricular infu-
sion of GABAARmAbs. Table S1 presents sequence and reactivity
data from GABAAR encephalitis CSF antibody repertoire. It lists
Ig sequence features and reactivity characteristics for mAbs
with corresponding identifier (mAb ID) isolated from CSF cells
of different phenotypes, including ASCs, MBCs, and NMBCs.
Table S2 shows regression models for GABAAR mAb binding to
unfixed murine brain. Table S3 characterizes disease symp-
tomatology in GABAAR encephalitis mouse model. Video 1 shows
catatonia and epileptic seizures in mice after intrathecal infu-
sion of GABAAR mAbs. Video 2 is a recording of a Racine stage 5
seizure in a rat after intrathecal infusion of GABAAR.
Data availability
Raw data were generated at the German Center for Neurode-
generative Diseases (DZNE) Berlin, Charité University Medicine
Berlin, Aston University Birmingham, University Hospital Jena,
and National Institute for Physiological Sciences Okazaki. All
relevant data supporting the key findings of this study are
available within the article and its supplementary information
files. The sequencing information for all mAbs from this man-
uscript, including raw data files and data derived from custom
BASE software analysis, have been deposited to Code Ocean
(https://doi.org/10.24433/CO.5442144.v1). The custom software
BASE used for Ig sequence analysis is available at https://github.
com/automatedSequencing/BASE.
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Figure S1. Characterization of reactivity and Ig sequence features from mAbs of GABAAR encephalitis CSF repertoire. (A) Gating strategy in
fluorescence-activated cell sorting is shown for isolation of CSF single cells for recombinant mAb cloning. CD3−CD14−CD16−DAPI− lymphocytes (top left) were
gated for CD138+ antibody-secreting cells (top right) or CD20+ B cells (bottom left), further differentiated into CD27+ MBCs and CD27− NMBCs (bottom right).
(B) Immunofluorescence stainings of recombinant human mAbs (green, as indicated in column caption) to HEK cells overexpressing the α1β3- or α1β3γ2-
subunits of GABAAR or untransfected controls (as indicated in row caption). Costaining with commercial α1-specific antibody is shown in red and nuclei staining
with DAPI in blue. Representative scale bar indicates 20 µm. (C) Ig subclass distributions per mAb source cell type from GABAAR encephalitis CSF repertoire.
(D and E) Absolute frequencies of GABAAR-reactive (GABAAR+) and GABAAR-negative (GABAAR−) mAbs per Ig subclass (D) and mAb source cell type (E).
(F) Comparison of SHM counts in the variable domain V genes between mAbs of different source cell types, analyzed using ordinary one-way ANOVA followed
by post hoc Tukey’s multiple comparison (**, P ≤ 0.01; or not shownwhen P > 0.05). Each dot indicates one mAb, n = 5–46mAbs per group. Bars indicate mean
± SD (G) Comparison of SHM counts in the variable domain V genes between GABAAR+ and GABAAR− mAbs. Each dot indicates one mAb, n = 5–62 mAbs per
group. Bars indicate mean ± SD. (H) Relative frequencies of SHM per nucleotide within CDRs and FRs of GABAAR+ mAb genes, shown as mean ± SEM; n = 5.
(I) Mean ratios of replacement to silence (R/S) mutations within CDRs and FRs for all SHMs of all GABAAR+ mAb genes combined. (J–O) Concentration-
dependent binding of GABAAR+ mAbs to indicated polyreactivity-defining antigens in an ELISA-based assay in comparison to controls of strongly polyreactive
ED38, weakly polyreactive eiJB40, and nonpolyreactive #mGO53. Bars indicate mean ± SEM from duplicate measurements of n = 2 independent experiments.
All stainings were replicated at least twice on tissue or neurons from two different animals. dsDNA, double-stranded DNA; FSC, forward scatter; ssDNA, single-
stranded DNA.
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Figure S2. Brain tissue reactivity patterns of human GABAAR and GABAAR-negative mAbs. (A–D) Immunofluorescence stainings of selected human
GABAAR mAbs (green; DAPI nuclei in blue) on fixed murine brain tissue in costainings with commercial antibodies (red/pink) as indicated in the column caption
above. (A1) #113-115 intensively stained hippocampal neuropil throughout CA1 and CA2, most pronounced in stratum oriens (so) with hippocampal fimbria (fi)
and stratum radiatum (sr), revealing complete overlap with commercial α1-specific antibody-binding pattern (red; merge in yellow). (A2) Both antibodies
showed distinct staining of the ventral pallidum. (A3)Higher magnifications in confocal acquisition revealed a somatic staining pattern with complete overlap in
the granule cell layer (gcl) of the cerebellum. (B1) α1γ2-dependent #113-175 stained the olfactory bulb, overlapping with commercial α1-specific antibody, most
pronounced in the external plexiform layer (epl) and the molecular cell layer (mcl), whereas weaker in the internal plexiform layer (ipl) and the gcl. (B2 and B3)
In the cerebellum, the mcl and gcl patterns uncovered different GABAAR-expressing cell populations, some predominantly labeled by #113-175 (green, black
arrowhead), some by commercial antibody (red, white asterisk), and others equally double positive (yellow, white arrowhead). (C1) #113-201 and commercial
α1-specific antibody targeted the epl of the olfactory bulb. (C2 and C3) However, #113-201 additionally showed intense binding around blood vessels (bv) and
choroid plexus (cp), still detectable at dilutions below the GABAAR pattern detection (not shown). (D1) In cerebellar stainings, human mAb GABAAR–binding
pattern (shown for #113-115) clearly distinguished from MAP2-positive dendrites, most pronounced in the mcl (D2) and from vGAT-highlighted somata of the
pcl. (D3) In magnified confocal images, human mAb visualized GABAAR clusters throughout the mcl and on a subpopulation of cells within the gcl, shown with a
reticular MAP2 costaining. (E–H) Immunofluorescence stainings on unfixed murine brain tissue of human GABAAR mAb #113-201 or commercial antibodies
specific for indicated GABAAR β-subunits (green; DAPI nuclei in blue). mAb #113-201 bound to the gcl of the cerebellum with expected GABAAR expression, but
additionally also around blood vessels (bv) between the mcl of two neighboring gyri (E1) and to the choroid plexus (cp) in the ventricles (E2). Binding of
β-subunit–specific antibodies was not detected (F1, G1, and H1) around blood vessels or in choroid plexus (F2, G2, and H2), therefore indicating GABAAR-
independent binding of #113-201 in these locations, as β-subunits are essential for functional GABAARs. (I–P) Immunofluorescence stainings of human GA-
BAAR-negative mAbs (green; nuclei in blue) from GABAAR encephalitis patient’s CSF repertoire. (I) Germline mAb #113-111 highlighted large bv and cp tissue.
(J) #113-126 stained fine vessels, specifically in frontal cortex. (K) #113-128 targeted cp. (L) #113-171, the only GABAAR-negative mAb derived from an ASC,
showed a similar staining pattern as GABAAR mAbs, including intensive binding to the gcl and mcl molecular but not pcl of the cerebellum. (M) #113-204 was
reactive to the mcl and pcl of the cerebellum. (N) #113-210 stained intensively hippocampal neuropil, pronounced in the CA2 and CA3 region, fimbria of the
hippocampus (fi). (O and P) #113-220 targeted selectively granule cells in the cerebellum and revealed a punctuated pattern in the lateral septal nuclei. Scale
bars indicate 100 µm, 20 µm in the third row (A3–D3). alv, alveus; gp, guinea pig; pcl, Purkinje cell layer; rb, rabbit; sp, stratum pyramidale; vp, ventral pallidum.
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Figure S3. Characterization of GABAAR mAb binding to native receptors. (A) Overview of binding from patient’s polyclonal samples and derived re-
combinant GABAAR mAbs in CBAs using COS7 cells overexpressing individual or multiple GABAAR subunits as indicated. Examples are shown for α1β3γ2, α1β3,
β3, and γ2 in Fig. 2 A. Patient’s CSF and PPE showed CBA-binding patterns similar to the derived CSF mAbs with prominent α1 reactivity and additional weak
binding to COS7 cells expressing α2β3, α5β3 (both), and β3γ2 (PPE only). #113-101, #113-115, and #113-198 selectively target α1, as detecting cells expressing
α1β3 and α1β3γ2, but not β3 or γ2 alone (Fig. 2 A). Specificity was confirmed by the absence of reactivity to α2β3γ2, α3β3γ2, α4β3γ2, and α5β3γ2. #113-175
detects GABAAR only when α1 and γ2 are coexpressed, but not in any other combination containing a different α-subunit (α2–α5) with β3γ2 coexpression. mAb
#113-201 binds the subunits α1 and γ2 independently (Fig. 2 A). The α-subunit–mediated reactivity is specific to α1, as CBA overexpressing different α-subunits
(α2–α5) in combination with β3 was not detected. GABA-negative control #mGO53 showed no binding. All GABAAR-negative mAbs from patient’s CSF
repertoire with anti-neuronal reactivity (exemplarily shown for #113-109) and negative control #mGO53 showed no binding. Note that β3 alone is expressed
on the cell surface, but α1 alone is not (Ebert et al., 1999). (B–G) A flow cytometry approach analyzing HEK cells transfected with rat or human α1β3γ2 GABAAR
and EGFP was used to complement tissue-based quantification of GABAAR mAb binding to native receptors (Fig. 2 B). (B) Selection of cells for analysis was
based on sequential gating on a homogeneous cell population in forward scatter (FSC) and sideward scatter (SSC), single cells, live cells (negative for DAPI), and
lastly the population of 30% highest EGFP signal as a marker for transfection. (C) Concentration-dependent GABAAR mAb #113-115 binding to EGFP-positive
and thus GABAAR HEK cells in comparison to EGFP-negative HEK cells. Similar data were obtained from all GABAAR mAbs. (D and E) Relative MFI values were
used to model binding to HEK-expressed rat GABAAR (D) or human GABAAR (E) using nonlinear regression models for one site-specific binding (Table S2). Bars
indicate mean ± SEM from n = 3 experiments. (F and G) Regression model–derived Half Max concentrations (50% of saturation binding = MFImax) are compared
between the flow cytometry assays using rat or human α1β3γ2 GABAAR and the murine tissue–binding assay (Fig. 2 A): The correlations indicate generally
similar binding between assays (R = −0.70, P = 0.23 in F; R = −0.21, P = 0.77 in G), with the exception of #113-201, which bound weakly to murine and rat
GABAAR but was the strongest binder to human GABAAR. (H) For analysis of competitive binding (in addition to Fig. 2 C), fluorophore-coupled GABAAR mAb
#113-101 was stained on unfixed murine brain tissue in combination with GABAAR mAbs as full IgG or Fab in excess as indicated. Quantified mean MFIs as
relative values to noncompetition conditions are shown as a heat map, each from 30 ROIs from two independent experiments. Receptor binding competition is
visualized in black and signal enhancement in yellow. (I) An ELISA assay was used to exclude binding of #113-101 to the variable domain of the #113-115. High-
binding plates were coated with commercial anti-human IgGMT145 or Fab fragments of control mAb #mGO53 or GABAARmAb #113-115 as indicated in column
group titles above. Sample mAbs (human IgG or Fab) were then applied as indicated in column labels below and detected using commercial detection antibody
MT78-ALP. Note that MT145 and MT78-ALP are Fc specific; thus, Fabs could not be detected when used as sample mAb. Bars indicate mean + SD from
triplicates of n = 2 experiments. (J) A control ELISA assay was used to confirm successful coating of Fab fragments to high-binding plates. Plates were coated as
above before application of commercial mouse anti-FLAG antibody (as sample mAb) for capture by Fab fragments. Bars indicate mean + SD from triplicates of
n = 2 experiments.
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Figure S4. Quantification of protein expression from cultured neurons treated with GABAARmAbs. (A–C) Representative Western blots of total protein
(TP) and biotinylated surface protein (SP) samples from neocortical rat neurons after preincubation with indicated GABAAR or control mAb #mGO53. Blots
were stained with commercial antibodies against the α1-subunit of GABAAR (A), the GluR1-subunit of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptors (B), and N-Cadherin (C). Quantifications of protein levels are shown in Fig. 4, G–J. (D)Quantification of human IgG from neocortical rat neuron culture
media used for Western blotting experiments (Fig. S4, A–C; and Fig. 3, G–J). The reduction of IgG was measured as the relative difference between post-
treatment medium and matched source medium samples, which have not been applied to the culture [relative reduction = (concentrationsource medium −
concentrationpost-treatment medium)/concentrationsource medium]. Bars indicate mean ± SEM; n = 6 experiments from two separate cultures. (E) Representative
immunofluorescence staining of post-treatment neuronal culture medium containing mAb #113-115 on an unfixed murine brain section confirmed GABAAR
reactivity of the antibody by typical staining pattern, as shown here in hippocampus. Scale bar indicates 500 µm. (F) Quantifications of GABAAR surface levels
from reader-based immunohistochemistry recordings from neocortical rat neurons after preincubation with indicated human GABAAR or control mAbs.
Representative recording is shown on top from neurons after live staining with a commercial antibody against the α1-subunit of GABAAR. Quantifications
revealed no difference. Bars indicate mean ± SEM; n = 6 experiments from three separate cultures.
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Figure S5. Competition of mAb #113-115 Fab and #113-115 IgG for binding to murine brain tissue. (A) To confirm competitive binding to the identical
target GABAAR mAb #113-115 as Fab fragment was stained at serial dilutions as indicated in the presence of fluorophore-coupled #113-115 IgG (#113-
115–CF488) at threshold concentration of 0.4 µg/ml (green). Binding of Fab was visualized using an anti-FLAG secondary antibody (red; nuclei in blue). The MFI
was measured separately for Fab and IgG binding in identical ROIs within granule cells of the cerebellum. Representative scale bar indicates 100 µm. (B) MFI
values from 18 ROIs of n = 2 independent experiments are shown as mean ± SEM. (C) Representative EEG recording from GABAAR mAb–infused rat is shown
with an example of a Racine stage 5 seizure with video-EEG and closeups of different EEG patterns during the recorded seizure. The corresponding video is
included as Video 2. (D) Distribution of the detected ictal events over time as analyzed with Neuroarchiver seizure detection software in a subgroup of three
animals that were recorded for a prolonged period of 21 d and that had received GABAAR mAb infusion over 7 d (red bar). Data from 7-d recording period for all
animals including controls is shown as Fig. 5 D. (E) From the same animals, the post seizure behavioral battery (PSBB) tests were performed and scored for
21 d. The dotted line represents the PSBB score of 10, above which the animals are likely to demonstrate aggresion and hyperexcitability on testing, which
strongly correlates with the development of spontaneous recurrent seizures. Bars indicate mean ± SEM. cv-inf, cerebroventricular infusion.
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Video 1. Catatonia and epileptic seizures in mice after intrathecal infusion of GABAAR mAbs. (A) Control mouse receiving high-dose control IgG showed
normal explorative behavior 3 d after intrathecal infusion. (B) In contrast, infusion of high-dose GABAAR mAb #113-115 led to severe catatonia and focal
epileptic seizures after 3 d. (C) Direct comparison of spontaneous behavior in mice receiving either GABAAR (left) or control mAb #mGO53 (right). (D) In mice
receiving lower doses of GABAAR mAb, catatonia and focal seizures occurred later (day 6) and were less pronounced. (E)Worsening of motor abnormalities at
day 10 in animals receiving high-dose GABAAR mAb with hyperexcitability and increased seizure frequency. (F) In contrast, control mice remained healthy and
showed normal explorative behavior after 14 d of intrathecal mAb infusion. conc., concentration; d3, day 3; d4, day 4; HL, heavy λ; HK, heavy κ.
Video 2. Video recording of Racine stage 5 seizure in a rat after intrathecal infusion of GABAAR. Video shows clinical presentation of the seizure
corresponding to the EEG recording shown in Fig. S5 C.
Provided online are three tables. Table S1 presents sequence and reactivity data from GABAAR encephalitis CSF antibody repertoire.
It lists Ig sequence features and reactivity characteristics formAbswith corresponding identifier (mAb ID) isolated from CSF cells of
different phenotypes, including ASCs, MBCs, and NMBCs. Table S2 shows regression models for GABAAR mAb binding to unfixed
murine brain. Table S3 characterizes disease symptomatology in GABAAR encephalitis mouse model.
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